Mirum Pharmaceuticals Competitors

Mirum Pharmaceuticals (NASDAQ:MIRM) and IGM Biosciences (NASDAQ:IGMS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, earnings, risk, profitability and valuation.

Institutional and Insider Ownership

72.9% of Mirum Pharmaceuticals shares are owned by institutional investors. Comparatively, 47.6% of IGM Biosciences shares are owned by institutional investors. 45.5% of Mirum Pharmaceuticals shares are owned by company insiders. Comparatively, 79.3% of IGM Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Mirum Pharmaceuticals and IGM Biosciences' top-line revenue, earnings per share (EPS) and valuation.

IGM Biosciences is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Mirum Pharmaceuticals and IGM Biosciences' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Mirum Pharmaceuticals and IGM Biosciences, as reported by MarketBeat.

Mirum Pharmaceuticals presently has a consensus target price of $40.1667, indicating a potential upside of 129.66%. IGM Biosciences has a consensus target price of $98.8750, indicating a potential upside of 50.04%. Given Mirum Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Mirum Pharmaceuticals is more favorable than IGM Biosciences.

Volatility & Risk

Mirum Pharmaceuticals has a beta of 2.44, indicating that its share price is 144% more volatile than the S&P 500. Comparatively, IGM Biosciences has a beta of -1.12, indicating that its share price is 212% less volatile than the S&P 500.

Summary

Mirum Pharmaceuticals beats IGM Biosciences on 7 of the 11 factors compared between the two stocks.

Ligand Pharmaceuticals (NASDAQ:LGND) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation and analyst recommendations.

Institutional and Insider Ownership

72.9% of Mirum Pharmaceuticals shares are held by institutional investors. 10.6% of Ligand Pharmaceuticals shares are held by insiders. Comparatively, 45.5% of Mirum Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Ligand Pharmaceuticals and Mirum Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Ligand Pharmaceuticals has higher revenue and earnings than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ligand Pharmaceuticals and Mirum Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent recommendations for Ligand Pharmaceuticals and Mirum Pharmaceuticals, as provided by MarketBeat.com.

Ligand Pharmaceuticals currently has a consensus price target of $214.00, indicating a potential upside of 70.72%. Mirum Pharmaceuticals has a consensus price target of $40.1667, indicating a potential upside of 129.66%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Mirum Pharmaceuticals is more favorable than Ligand Pharmaceuticals.

Volatility & Risk

Ligand Pharmaceuticals has a beta of 1.46, suggesting that its share price is 46% more volatile than the S&P 500. Comparatively, Mirum Pharmaceuticals has a beta of 2.44, suggesting that its share price is 144% more volatile than the S&P 500.

Summary

Mirum Pharmaceuticals beats Ligand Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Arcus Biosciences (NYSE:RCUS) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation and analyst recommendations.

Profitability

This table compares Arcus Biosciences and Mirum Pharmaceuticals' net margins, return on equity and return on assets.

Institutional and Insider Ownership

60.6% of Arcus Biosciences shares are held by institutional investors. Comparatively, 72.9% of Mirum Pharmaceuticals shares are held by institutional investors. 19.7% of Arcus Biosciences shares are held by insiders. Comparatively, 45.5% of Mirum Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations for Arcus Biosciences and Mirum Pharmaceuticals, as provided by MarketBeat.com.

Arcus Biosciences currently has a consensus price target of $51.50, indicating a potential upside of 76.67%. Mirum Pharmaceuticals has a consensus price target of $40.1667, indicating a potential upside of 129.66%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Mirum Pharmaceuticals is more favorable than Arcus Biosciences.

Volatility & Risk

Arcus Biosciences has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Comparatively, Mirum Pharmaceuticals has a beta of 2.44, suggesting that its share price is 144% more volatile than the S&P 500.

Valuation & Earnings

This table compares Arcus Biosciences and Mirum Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Mirum Pharmaceuticals has lower revenue, but higher earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Mirum Pharmaceuticals beats Arcus Biosciences on 9 of the 14 factors compared between the two stocks.

Mirum Pharmaceuticals (NASDAQ:MIRM) and Revance Therapeutics (NASDAQ:RVNC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, profitability, earnings and analyst recommendations.

Profitability

This table compares Mirum Pharmaceuticals and Revance Therapeutics' net margins, return on equity and return on assets.

Institutional and Insider Ownership

72.9% of Mirum Pharmaceuticals shares are owned by institutional investors. Comparatively, 74.4% of Revance Therapeutics shares are owned by institutional investors. 45.5% of Mirum Pharmaceuticals shares are owned by company insiders. Comparatively, 4.8% of Revance Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings for Mirum Pharmaceuticals and Revance Therapeutics, as provided by MarketBeat.

Mirum Pharmaceuticals currently has a consensus target price of $40.1667, indicating a potential upside of 129.66%. Revance Therapeutics has a consensus target price of $38.50, indicating a potential upside of 37.84%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Mirum Pharmaceuticals is more favorable than Revance Therapeutics.

Risk & Volatility

Mirum Pharmaceuticals has a beta of 2.44, meaning that its share price is 144% more volatile than the S&P 500. Comparatively, Revance Therapeutics has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500.

Valuation and Earnings

This table compares Mirum Pharmaceuticals and Revance Therapeutics' revenue, earnings per share and valuation.

Mirum Pharmaceuticals has higher earnings, but lower revenue than Revance Therapeutics. Revance Therapeutics is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Mirum Pharmaceuticals beats Revance Therapeutics on 10 of the 14 factors compared between the two stocks.

Mirum Pharmaceuticals (NASDAQ:MIRM) and Dicerna Pharmaceuticals (NASDAQ:DRNA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, profitability, earnings and analyst recommendations.

Profitability

This table compares Mirum Pharmaceuticals and Dicerna Pharmaceuticals' net margins, return on equity and return on assets.

Institutional and Insider Ownership

72.9% of Mirum Pharmaceuticals shares are owned by institutional investors. Comparatively, 80.6% of Dicerna Pharmaceuticals shares are owned by institutional investors. 45.5% of Mirum Pharmaceuticals shares are owned by company insiders. Comparatively, 11.3% of Dicerna Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings for Mirum Pharmaceuticals and Dicerna Pharmaceuticals, as provided by MarketBeat.

Mirum Pharmaceuticals currently has a consensus target price of $40.1667, indicating a potential upside of 129.66%. Dicerna Pharmaceuticals has a consensus target price of $42.2857, indicating a potential upside of 64.41%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Mirum Pharmaceuticals is more favorable than Dicerna Pharmaceuticals.

Risk & Volatility

Mirum Pharmaceuticals has a beta of 2.44, meaning that its share price is 144% more volatile than the S&P 500. Comparatively, Dicerna Pharmaceuticals has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500.

Valuation and Earnings

This table compares Mirum Pharmaceuticals and Dicerna Pharmaceuticals' revenue, earnings per share and valuation.

Mirum Pharmaceuticals has higher earnings, but lower revenue than Dicerna Pharmaceuticals. Dicerna Pharmaceuticals is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Mirum Pharmaceuticals beats Dicerna Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Mirum Pharmaceuticals (NASDAQ:MIRM) and FibroGen (NASDAQ:FGEN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, profitability, earnings and analyst recommendations.

Profitability

This table compares Mirum Pharmaceuticals and FibroGen's net margins, return on equity and return on assets.

Institutional and Insider Ownership

72.9% of Mirum Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.1% of FibroGen shares are owned by institutional investors. 45.5% of Mirum Pharmaceuticals shares are owned by company insiders. Comparatively, 3.4% of FibroGen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings for Mirum Pharmaceuticals and FibroGen, as provided by MarketBeat.

Mirum Pharmaceuticals currently has a consensus target price of $40.1667, indicating a potential upside of 129.66%. FibroGen has a consensus target price of $47.00, indicating a potential upside of 122.43%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Mirum Pharmaceuticals is more favorable than FibroGen.

Risk & Volatility

Mirum Pharmaceuticals has a beta of 2.44, meaning that its share price is 144% more volatile than the S&P 500. Comparatively, FibroGen has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500.

Valuation and Earnings

This table compares Mirum Pharmaceuticals and FibroGen's revenue, earnings per share and valuation.

Mirum Pharmaceuticals has higher earnings, but lower revenue than FibroGen. FibroGen is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Mirum Pharmaceuticals beats FibroGen on 9 of the 14 factors compared between the two stocks.